The full result from Eisai’s large, global phase 3 confirmatory Clarity AD clinical study of lecanemab – an investigational anti-amyloid ... baseline – such as acetylcholinesterase ...

Lecanemab has given us more years together. That’s not ‘minute’ nor ‘minimal’ to me,” writes one reader in STAT’s letters to ...

Researchers from Osaka University find that peristaltic pump action and high shear flow forces promote amyloid nucleation.

The factor that tips you over the edge from being at risk for a disease to actually developing the disease is not always ...

Researchers from Osaka University found that peristaltic pump flow mechanically breaks supersaturation to induce amyloid ...

It eventually led to Still being diagnosed with ATTR amyloidosis, a rare genetic condition that causes heart problems, neuropathy, and ligament and tendon troubles. Since his diagnosis in ...

The FDA granted Regenerative Medicine Advanced Therapy designation to NXC-201 for the treatment of relapsed/refractory light ...

More than 2 years since the original trial data for lecanemab in Alzheimer's disease was published,1 and over 1·5 years since approval by the US Food and Drug Administration, brain volume data have ...

Alzheimer's disease (AD), the most common form of dementia, continues to remain one of modern medicine's greatest challenges.

Brain inflammation, while a crucial part of the body's immune response, takes on a detrimental role in Alzheimer's disease.

Neck pain can disrupt sleep and throw off your spinal alignment. While a top-quality new mattress helps, your pillow plays a critical role in supporting the natural curve of your neck ...

A Phase III trial evaluating nex-z in transthyretin amyloidosis with cardiomyopathy is underway, with plans for another ...